Expert review of respiratory medicine · 2025
Inhaled nitric oxide in therapy of pediatric and neonatal acute respiratory distress syndrome: the good, the bad and the ugly.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Qi, Liu Shuyue, Tang Wenwen, Gao Xiaoyan, Li Bingbing, Liang Chenlu, Lorimer George H, Bayram Hasan, Wang Jun
Аннотация
INTRODUCTION: Pediatric and neonatal acute respiratory distress syndrome (PARDS/NARDS) cause significant mortality or long-term morbidity in childhood. The optimal management remains elusive, making a review of therapies like inhaled nitric oxide (iNO) timely and crucial.
AREAS COVERED: This review elucidates the mechanisms of iNO and critically appraises its application in PARDS/NARDS. A literature search covering the period up to December 2024 was conducted in PubMed, Embase, and Web of Science. We evaluated its effects on oxygenation, inflammation, and outcomes, highlighting the inconclusive impact on survival and neurodevelopment, and the limitations posed by variable response and safety concerns.
EXPERT OPINION: While iNO can improve oxygenation, its routine use is not recommended due to uncertain long-term benefits. Future, rigorous trials must identify predictive biomarkers and patient subgroups most likely to benefit, paving the way for personalized iNO therapy in neonatal and pediatric critical care.
AREAS COVERED: This review elucidates the mechanisms of iNO and critically appraises its application in PARDS/NARDS. A literature search covering the period up to December 2024 was conducted in PubMed, Embase, and Web of Science. We evaluated its effects on oxygenation, inflammation, and outcomes, highlighting the inconclusive impact on survival and neurodevelopment, and the limitations posed by variable response and safety concerns.
EXPERT OPINION: While iNO can improve oxygenation, its routine use is not recommended due to uncertain long-term benefits. Future, rigorous trials must identify predictive biomarkers and patient subgroups most likely to benefit, paving the way for personalized iNO therapy in neonatal and pediatric critical care.